BMRN vs TNGX · P/E 40, rev $1.76B vs $5.36B cap
Biomarin Pharmaceutical Inc (BMRN) versus Tango Therapeutics Inc (TNGX) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Tango Therapeutics Inc (TNGX) is a biotechnology company listed on NASDAQ.
Latest reported BMRN revenue for 2026-06-30 was $1.76B. Net income was $150.3M. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported TNGX revenue for 2026-06-30 was $0. Net income was -$100.9M. TNGX currently screens at market cap $5.36B.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. TNGX currently screens at market cap $5.36B.
Not investment advice. Open the BMRN and TNGX stock pages for the full models.
Not investment advice.